72
Participants
Start Date
May 29, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
June 30, 2028
JS207
10 mg/kg q3W or adjust the dose (e.g. 15 mg/kg) based on accumulated data on the safety and efficacy of JS207 from clinical studies.
JS007
Dose exploration stage: C1-C4, group 1:3 mg/kg, C1D1 once (single dose); Group 2:3 mg/kg, D1, Q6W; Group 3:1 mg/kg,D1, Q3W; ≥C5, 1 mg/kg, Q6W; Dose expansion stage: according to the group medication confirmed in the dose exploration stage.
RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Zhongshan Hospital affiliated to Fudan University, Shanghai
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine City:Shanghai, Shanghai
NOT_YET_RECRUITING
Shanghai East Hospital,School of Medicine, Tongji University, Shanghai
RECRUITING
The First Affiliated Hospital of USTC, Hefei
RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Shanghai Junshi Bioscience Co., Ltd.
OTHER